GlassScriptPhysician profile
Michael J Yanish
NPI 1316913262
$4,360.12
in general payments reported to CMS, 2019-2025
29 companies · $32.29 in 2025
The $32.29 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $282 · 2021: $16.86 · 2022: $793 · 2023: $1,016 · 2024: $1,174 · 2025: $32.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.99 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Gilead Sciences, INC. | $879.29 | 2019-2024 | |
| Janssen Biotech, INC. | $526.62 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $453.32 | 2019-2024 | Entyvio, Gattex |
| Celgene Corporation | $228.36 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $178.39 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $128.16 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $123.69 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.80 | 2019-2023 | Xifaxan |
| Shionogi INC | $93.56 | 2019-2020 | |
| Genzyme Corporation | $80.35 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $77.43 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $73.26 | 2024 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $65.40 | 2022-2023 | |
| Pfizer INC. | $63.56 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.29 | 2019-2024 | Dificid |
| Fresenius Kabi USA, LLC | $50.87 | 2023-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $36.01 | 2023 | Cimzia |
| Madrigal Pharmaceuticals | $32.29 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $29.17 | 2024 | Dupixent |
| Daiichi Sankyo INC. | $28.07 | 2019 | |
| Redhill Biopharma INC. | $27.32 | 2023 | Talicia, Movantik, Aemcolo |
| Allergan, INC. | $24.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.55 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $20.61 | 2024 | |
| Oxford Immunotec USA INC | $15.43 | 2022 | |
| Celltrion USA INC. | $14.93 | 2024 | Vegzelma |
| Ucb, INC. | $13.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yanish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.